Business Context and Reporting Period
This Form 8-K was filed by Omeros Corporation on September 2, 2015, reporting events occurring on September 2 and September 3, 2015. The filing concerns legal actions taken by the company to protect the patent rights for its drug Omidria (phenylephrine and ketorolac injection) 1%/0.3%.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific legal event rather than financial performance.
Material Changes
The material change reported is the initiation of patent infringement litigation against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC. Omeros filed lawsuits in the U.S. District Court for the District of New Jersey and the District of Delaware alleging infringement of three patents (U.S. Patent Nos. 8,173,707, 8,586,633, and 9,066,856) listed in the FDA Orange Book.
Guidance, Outlook, and Risks
- Legal Strategy: The lawsuits were filed in response to a Paragraph IV certification notice from Par regarding an Abbreviated New Drug Application (ANDA) for a generic version of Omidria.
- Regulatory Impact: Under the Hatch-Waxman Act, the filing triggers a 30-month stay on the FDA's approval of Par's ANDA. This stay is expected to remain in effect until March 2018.
- Management Commentary: Omeros believes Par's assertions of non-infringement or invalidity lack merit. The company intends to vigorously prosecute its claims.
- Contingencies: Omeros has sought access to Par's ANDA as required by law, but Par has not yet provided this access. The company states it will obtain access to proceed with the litigation.
Key Facts for Investor Verification
- Confirmation of the 30-month stay on generic approval extending to March 2018.
- Progress on obtaining access to Par's ANDA for litigation purposes.
- Any updates on the status of the lawsuits filed in New Jersey and Delaware.
- Impact of the litigation on Omidria's projected revenue timeline.